@OncLive
Pinned post
www.onclive.com Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC | OncLive The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine. 
www.onclive.com Dr Banks on the Feasibility of Lifileucel in Select Metastatic Sarcomas | OncLive Lauren Banks, MD, PhD, discusses feasibility findings for lifileucel in select metastatic sarcomas and next steps with the phase 2 SARATOGA trial. 
www.onclive.com Dr Moser on Outcomes for WTX-124 ± Pembrolizumab in Advanced Immune-Sensitive Solid Tumors | OncLive Justin Moser, MD, discusses safety and activity of the IL-2 prodrug WTX-124 alone or with pembrolizumab in immune-sensitive solid tumors. 
